CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 200 enrolled
Drug / intervention
Triptorelin acetatedrug
Likely dose
Triptorelin acetate 3,75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01581359
NCT01581359Phase 4Completed
CompareCT.gov

A Comparative Study, Randomized, Blinded, About the Effect of Pre-treatment With GnRH Analogues Versus Placebo in Infertile Patients With Endometriosis Undergoing in Vitro Fertilization Treatment

Instituto de Investigacion Sanitaria La Fe·interventional·Posted Apr 20, 2012·Updated Oct 22, 2015

In Brief

A Phase 4 clinical trial evaluating Triptorelin acetate for Endometriosis and Infertility. Completed, enrolled 200 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether the administration of an analogue of gonadotropin-releasing hormone (GnRH) during the three months prior to the performing of an IVF may improve the response to ovarian stimulation, implantation rate and clinical pregnancy rate in patients with endometriosis/ endometriomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis, Infertility
CountriesSpain
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 20, 2012
Enrollment StartMar 1, 2012
Primary CompletionMar 1, 2015
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 14.2 years ago

Interventions

Triptorelin acetatedrug

* Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses * Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses